Trial Profile

INFORM-2

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 19 Feb 2010

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Danoprevir (Primary) ; Mericitabine (Primary) ; Peginterferon alfa-2a; Ribavirin
Indications Hepatitis C
Focus Therapeutic Use
Acronyms INFORM-2
Sponsors Roche

Most Recent Events

19 Feb 2010 Status changed from planning to discontinued, according to a Pharmasset media release.
19 Nov 2009 New trial record.
03 Nov 2009 The projected initiation date for this trial is in the first quarter of 2010, according to information presented in a Pharmasset media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com